Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00707954
Recruitment Status : Completed
First Posted : July 1, 2008
Results First Posted : April 28, 2014
Last Update Posted : April 28, 2014
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days). Dose escalation design is utilized in this study, and dose escalation of TA-7284 will be starting with 25 mg (step 1). Subsequent doses of 100 mg (step 2), 200 mg (step 3) and 400 mg (step 4) are planned after review of the tolerance and PK of the previous step.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: TA-7284 Drug: Placebo of TA-7284 Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus
Study Start Date : June 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: TA-7284 Drug: TA-7284
Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Placebo Comparator: Placebo of TA-7284 Drug: Placebo of TA-7284
Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)

Primary Outcome Measures :
  1. Safety: Adverse Events, Adverse Drug Reactions [ Time Frame: 19 days ]
    In the safety analysis population, adverse events incidences and adverse drug reactions incidences were calculated by dose.

Secondary Outcome Measures :
  1. Pharmacokinetics- 1)Plasma Concentration of TA-7284: Tmax,Cmax, AUC, Etc.; and 2)Urinary Excretion of TA-7284: Ae, Ae%, CLr [ Time Frame: 19 days ]
  2. Pharmacodynamics- 1)Urinary Glucose Excretion; 2)Plasma Glucose Concentration; 3)Insulin Concentration in Serum; 4)Insulinogenic Index;and 5)Hemoglobin A1c and Glycoalbumin [ Time Frame: 18 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically stable Type 2 Diabetes Mellitus
  • Females without childbearing potential
  • Body mass index (BMI) >= 18.5 kg/m2 and <= 39.9 kg/m2
  • Hemoglobin A1c levels >= 6.5% and <= 10%
  • Fasting blood glucose levels >= 140 mg/dL and <= 270 mg/dL
  • Systolic blood pressure >= 95 mmHg and <= 160 mmHg, and diastolic blood pressure >= 50 mmHg and <= 100 mmHg, and pulse rate >= 50 bpm
  • Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing
  • Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months
  • Treatment with diet and exercise should be unchanged for more than 3 months

Exclusion Criteria:

  • Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus
  • History of diabetic complications which need treatment
  • Treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or systemic steroids within 3 months prior to informed consent
  • Serum creatinine > upper limit of the normal range
  • Patients with significant complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00707954

P-One Clinic
Hachioji-city, Tokyo-to, Japan
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Study Director: Kazuoki Kondo, MD Mitsubishi Tanabe Pharma Corporation

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mitsubishi Tanabe Pharma Corporation Identifier: NCT00707954     History of Changes
Other Study ID Numbers: TA-7284-02
First Posted: July 1, 2008    Key Record Dates
Results First Posted: April 28, 2014
Last Update Posted: April 28, 2014
Last Verified: March 2014

Keywords provided by Mitsubishi Tanabe Pharma Corporation:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases